Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
102 hedge funds and large institutions have $128M invested in Antares Pharma, Inc. in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 26 increasing their positions, 33 reducing their positions, and 17 closing their positions.
16% more capital invested
Capital invested by funds: $110M → $128M (+$17.5M)
4% more call options, than puts
Call options by funds: $117K | Put options by funds: $112K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 110 → 102 (-8)
21% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 33
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$11.2M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$2M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.13M |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$876K |
| 5 |
JP Morgan Chase
New York
|
+$850K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$7.45M |
| 2 |
Renaissance Technologies
New York
|
-$1.19M |
| 3 |
BlackRock
New York
|
-$449K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$311K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$300K |
ATRS Hedge Fund Activity: Q1 2018 in Review
102 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q1 2018, worth a combined $128M — up 16% from $110M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ATRS and 10 opened new positions — a net loss of 7 holders — while 33 trimmed existing stakes and 26 added.
The largest buyer was Armistice Capital, adding an estimated $11.2M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $7.45M sold.
- 102 institutional investors held Antares Pharma, Inc. (ATRS) as of Q1 2018, down from 110 in Q4 2017.
- Funds reported $128M of Antares Pharma, Inc. stock for Q1 2018, up 16% quarter-over-quarter.
- 10 funds opened new Antares Pharma, Inc. positions in Q1 2018 and 17 closed out, a net change of -7 holders.
- The largest Antares Pharma, Inc. buyer in Q1 2018 was Armistice Capital, an estimated $11.2M added.
- The largest Antares Pharma, Inc. seller in Q1 2018 was Perceptive Advisors, an estimated $7.45M sold.
Based on aggregated 13F filings for Q1 2018.